Quest Diagnostics Incorporated $DGX Stock Sold by Aberdeen Group plc

Aberdeen Group plc lessened its position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 50.4% during the third quarter, Holdings Channel reports. The fund owned 41,209 shares of the medical research company’s stock after selling 41,882 shares during the period. Aberdeen Group plc’s holdings in Quest Diagnostics were worth $9,605,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Yousif Capital Management LLC raised its holdings in shares of Quest Diagnostics by 67.3% during the 3rd quarter. Yousif Capital Management LLC now owns 25,173 shares of the medical research company’s stock valued at $5,867,000 after purchasing an additional 10,122 shares in the last quarter. Bank OZK bought a new stake in Quest Diagnostics during the 2nd quarter valued at approximately $3,247,000. Assenagon Asset Management S.A. grew its stake in shares of Quest Diagnostics by 39.1% in the second quarter. Assenagon Asset Management S.A. now owns 15,405 shares of the medical research company’s stock worth $3,265,000 after acquiring an additional 4,334 shares during the last quarter. SGL Investment Advisors Inc. acquired a new stake in Quest Diagnostics in the 2nd quarter worth $6,485,000. Finally, BlackRock Inc. bought a new position in Quest Diagnostics during the second quarter valued at about $1,965,923,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Patrick Plewman sold 11,717 shares of Quest Diagnostics stock in a transaction on Monday, November 9th. The stock was sold at an average price of $257.34, for a total value of $3,015,252.78. Following the transaction, the senior vice president owned 14,684 shares in the company, valued at approximately $3,778,780.56. This trade represents a 44.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary Pfeiffer sold 1,203 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $243.00, for a total transaction of $292,329.00. Following the completion of the sale, the director owned 29,802 shares in the company, valued at approximately $7,241,886. The trade was a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 79,478 shares of company stock worth $19,794,031 in the last three months. Company insiders own 0.88% of the company’s stock.

Quest Diagnostics Trading Up 1.1%

Shares of NYSE:DGX opened at $259.17 on Thursday. The business has a 50 day moving average of $242.61 and a 200-day moving average of $216.71. The stock has a market cap of $28.51 billion, a PE ratio of 23.22, a P/E/G ratio of 2.30 and a beta of 0.55. Quest Diagnostics Incorporated has a 12-month low of $171.18 and a 12-month high of $263.19. The company has a quick ratio of 1.58, a current ratio of 1.70 and a debt-to-equity ratio of 0.70.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings data on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.87 by $0.13. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The firm had revenue of $3.10 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter last year, the business earned $2.60 EPS. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. As a group, equities research analysts forecast that Quest Diagnostics Incorporated will post 11.29 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 27th. Investors of record on Tuesday, January 12th will be given a dividend of $0.86 per share. The ex-dividend date of this dividend is Tuesday, January 12th. This represents a $3.44 annualized dividend and a yield of 1.3%. Quest Diagnostics’s dividend payout ratio is currently 34.26%.

Analysts Set New Price Targets

A number of analysts recently weighed in on DGX shares. Robert W. Baird set a $262.00 price target on shares of Quest Diagnostics in a report on Friday, October 23rd. JPMorgan Chase & Co. boosted their price target on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. UBS Group restated a “neutral” rating and set a $250.00 target price on shares of Quest Diagnostics in a report on Monday, October 19th. Mizuho upped their price objective on Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Finally, Argus set a $260.00 price target on shares of Quest Diagnostics in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $248.70.

View Our Latest Stock Report on DGX

About Quest Diagnostics

(Free Report)

Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.

Recommended Stories

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.